This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Company News for Dec 5, 2019
by Zacks Equity Research
Companies In The News Are: HQY, CRM, CPB, RY
Here's Why You Should Hold on to HealthEquity (HQY) for Now
by Zacks Equity Research
Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.
HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q3
by Zacks Equity Research
Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.
HealthEquity (HQY) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 113.64% and 3.29%, respectively, for the quarter ended October 2019. Do the numbers hold clues to what lies ahead for the stock?
Teladoc (TDOC) Up 73% Year to Date: Will the Rally Continue?
by Sapna Bagaria
Teladoc's (TDOC) presence in the growing telehealth industry with many deal wins and international expansion is likely to drive long-term growth.
ERFSF vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ERFSF vs. HQY: Which Stock Is the Better Value Option?
ERFSF vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ERFSF vs. HQY: Which Stock Is the Better Value Option?
ERFSF or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ERFSF vs. HQY: Which Stock Is the Better Value Option?
HealthEquity (HQY) Down 5.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ERFSF vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ERFSF vs. HQY: Which Stock Is the Better Value Option?
HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q2
by Zacks Equity Research
HealthEquity (HQY) gains from solid segmental contributions in second-quarter fiscal 2020.
HealthEquity Acquires WageWorks, To Make Notable Investments
by Zacks Equity Research
HealthEquity (HQY) expects to complete its $80-100 million investment program within 24-36 months from now.
What's in the Cards for HealthEquity (HQY) in Q2 Earnings?
by Zacks Equity Research
Higher revenues and possible margin expansion are likely to aid HealthEquity (HQY) in Q2 earnings.
HealthEquity (HQY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
HealthEquity (HQY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HealthEquity (HQY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
HealthEquity (HQY) closed at $58.62 in the latest trading session, marking a +0.15% move from the prior day.
HealthEquity (HQY) Stock Moves -0.51%: What You Should Know
by Zacks Equity Research
In the latest trading session, HealthEquity (HQY) closed at $60.69, marking a -0.51% move from the previous day.
HealthEquity (HQY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
HealthEquity (HQY) closed at $68.50 in the latest trading session, marking a +1.41% move from the prior day.
HealthEquity (HQY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
HealthEquity (HQY) closed at $77.80 in the latest trading session, marking a -0.13% move from the prior day.
AMN or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. HQY: Which Stock Is the Better Value Option?
Has HealthEquity (HQY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (HQY) Outperforming Other Medical Stocks This Year?
Is HealthEquity (HQY) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
HealthEquity (HQY) possesses solid growth attributes, which could help it handily outperform the market.
HealthEquity (HQY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, HealthEquity (HQY) closed at $81.91, marking a +0.92% move from the previous day.
Near-Term Outlook for Medical Services Industry Looks Bright
by Urmimala Biswas
The third-party medical services industry is expanding rapidly.
AMN or HQY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. HQY: Which Stock Is the Better Value Option?
HealthEquity (HQY) in Focus: Stock Moves 6.7% Higher
by Zacks Equity Research
HealthEquity (HQY) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.